Skip to main content
Clinical Trials/NCT06131463
NCT06131463
Completed
Not Applicable

Assessing the Impact of Using the Electrocardiogram Function in Smart Watches on the Level of Anxiety (GAD-7) Among University Students and Employees

ITMO University1 site in 1 country71 target enrollmentNovember 13, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mental Health Wellness 1
Sponsor
ITMO University
Enrollment
71
Locations
1
Primary Endpoint
Anxiety level
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The integration of electrocardiography (ECG) functionality into smartwatches is primarily intended to screen for atrial fibrillation, a frequent cause of ischemic stroke, among people aged 50 years and older. However, it should be noted that recommendations for atrial fibrillation screening are controversial, and several organizations and communities do not recommend screening outside of at-risk groups.

Some smart device manufacturers do not recommend using the ECG function for anyone under the age of 22. However, young people are frequent users of wearable devices. One of the most common cardiologic diseases at the age of 18-30 is benign heart rhythm disorder, which often does not require diagnosis or treatment and can be considered normal.

That said, notification of the detection of atrial fibrillation can affect psycho-emotional well-being, particularly anxiety.

This study will assess the level of psycho-emotional health (anxiety level) of the study participants. Participant observation will provide an opportunity to identify associations between the use of the ECG recording function on wearable devices and levels of anxiety and depression. It is hypothesized that the use of smartwatches with the ECG function activated will not lead to a change in anxiety levels on the GAD-7 scale among the study participants. This assumes that after 30 days of use, the mean value of the GAD-7 scale in the intervention group and the control group will be the same.

Registry
clinicaltrials.gov
Start Date
November 13, 2023
End Date
March 4, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
ITMO University
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Status of a student or employee of ITMO University;
  • Availability of a smart watch with ECG function (Apple Watch Series 4 and newer, Galaxy Watch Active2, Samsung Galaxy Watch Series 3 and newer or similar with ECG function);
  • Availability of a Galaxy smartphone running Android 7.0 or newer or availability of an iPhone 8 and newer smartphone with the latest version of iOS.
  • Signed Informed consent and Consent for Data Processing of Personal Data;
  • Absence of previously diagnosed clinically significant cardiovascular pathology.

Exclusion Criteria

  • Participants under the age of 22 cannot be included in the study;
  • Participants in the acute phase of any disease or in the exacerbation of chronic diseases are excluded from the study.

Outcomes

Primary Outcomes

Anxiety level

Time Frame: 30 days

Anxiety level is measured 30 days after the enrolment with Generalized Anxiety Disorder 7-item (GAD-7) which is a tool based on seven items which are scored from zero to three. The whole scale score can range from 0 to 21 and cut-off scores for mild, moderate and severe anxiety symptoms are 5, 10 and 15 respectively.

Secondary Outcomes

  • Heart rhythm disturbances(90 days)
  • Depression(90 days)
  • Anxiety level(90 days)

Study Sites (1)

Loading locations...

Similar Trials